BULLISHWHALES
BullishWhales · Analysts · Analyst Profile

David Nierengarten

Wedbush · Equity Research Analyst

Analyst rating accuracy & track record

David Nierengarten does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
TLXTelix Pharmaceuticals Limited
Buy$22.00Jun 2025−60.4%Miss
NUVBNuvation Bio Inc
Buy$5.00May 2025+72.7%Hit
KNSAKiniksa Pharmaceuticals Ltd
Buy$34.00Apr 2025+114.1%Hit
CATXPerspective Therapeutics Inc.
Buy$11.00Mar 2025+69.6%Miss
IMNMImmunome Inc
Buy$33.00Mar 2025+143.7%Miss
BCAXBicara Therapeutics Inc. Common Stock
Buy$31.00Feb 2025−1.3%Miss
BCAXBicara Therapeutics Inc. Common Stock
Buy$31.00Feb 2025+17.0%Miss
SRRKScholar Rock Holding Corp
Buy$47.00Nov 2024+1.3%Miss
IMNMImmunome Inc
Buy$33.00Oct 2024+33.4%Miss
SYRESpyre Therapeutics Inc.
Buy$45.00Sep 2024−29.9%Miss
IMNMImmunome Inc
Buy$33.00Aug 2024−15.2%Miss
ARTVArtiva Biotherapeutics, Inc. Common Stock
Buy$18.00Aug 2024−66.0%Miss
KNSAKiniksa Pharmaceuticals Ltd
Buy$34.00Jul 2024+15.1%Miss
STROSutro Biopharma
Buy$8.00May 2024−70.8%Miss
IMNMImmunome Inc
Buy$33.00Apr 2024−71.7%Miss
IMNMImmunome Inc
Buy$19.00Jan 2024−37.5%Hit
KNSAKiniksa Pharmaceuticals Ltd
Buy$25.00Jan 2024−1.1%Hit
FENCFennec Pharmaceuticals Inc
Buy$19.00Sep 2022−10.5%Miss
Go to

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.

v1.0.30